CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RESPIRI-TB seeks to develop a new combination drug regimen for tuberculosis that is more effective and shorter in duration. The project focuses on targeting the energy metabolism of the bacteria and reducing drug resistance through innovative drug candidates.
Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide.
In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health.
Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs.
Mo…
Leiden University Medical Center
ACADEMISCH ZIEKENHUIS LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Belgium, Antwerpen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Paris
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
MEDIZINISCHE UNIVERSITAET WIEN
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
